RSA-RCT: Attune S+ TKA Versus Sigma TKA (APKnee2-S+)
Primary Purpose
Osteoarthritis Arthritis, Joint Disease, Musculoskeletal Disease
Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
ATTUNE S+ Knee Prosthesis by DePuy
PFC Sigma Knee Prosthesis by DePuy
Sponsored by
About this trial
This is an interventional treatment trial for Osteoarthritis Arthritis focused on measuring Comparative Study, Knee Prosthesis, Prosthesis Design, Treatment Outcome, Follow-Up Studies
Eligibility Criteria
Inclusion Criteria:
- Patient is diagnosed with osteoarthritis and requires primary knee arthroplasty
- All consecutive patients ("usual care") are included to prevent selection bias in the migration analysis.
- Patient is capable of giving informed consent and expressing a willingness to comply with this study
Exclusion Criteria:
The patient has an a-priori risk for a posterior-stabilized total knee arthroplasty.
- Insufficiency of the posterior cruciate ligament (PCL)
- Status after patellectomy
- In case flexion is less than 90 degrees
- The patient is diagnosed with Rheumatoid Arthritis
- When it is expected that the tibia cut during surgery will compromise the attachment of the PCL (because of bony defects)
- The patient is unable or unwilling to sign the Informed Consent specific to this study
- The patient does not understand the Dutch or English language good enough to participate
- Patients indicated for revision arthroplasty instruments because of bone defects or deformity of the bone
- When there are not enough markers visible in the baseline RSA photograph and it will not improve by placing the patient in another position, the patient will be excluded from the study (secondary exclusion criteria).
Sites / Locations
- Haaglanden Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
ATTUNE
PFC Sigma
Arm Description
Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Outcomes
Primary Outcome Measures
Migration, Maximum Total Point Motion (MTPM in mm) measured by means of Radiostereometry (RSA)
Compare the magnitude and pattern of migration of the prostheses (Tibial and Femoral component, smaller MTPM is better)
Migration is defined as the relative movement of the prosthesis with respect to the markers in the bone.
MTPM is defined as Maximum Total Point Motion, which means the amount of motion of the point that moves the most.
Secondary Outcome Measures
EQ-5D with 3 levels of severity for each of the 5 dimensions (EQ-5D-3L)
General Health: EuroQol 3 Dimensional (EQ-5D) Health Questionnaire measured using patient questionnaire; Index, 0 (worst possible) - 100 (best possible).
Knee injury and Osteoarthritis Outcome Score (KOOS-PS)
Knee Function: Knee injury and Osteoarthritis Outcome Score (KOOS) measured using patient questionnaire; Index, 0 (worst possible) - 100 (best possible).
Visual Analogue Scale (VAS) pain
Pain score after activity and during rest; Likert scale 0 (no-pain) -10 (extreme pain).
Full Information
NCT ID
NCT04037735
First Posted
July 26, 2019
Last Updated
September 16, 2019
Sponsor
Peter den Hollander
Collaborators
Leiden University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT04037735
Brief Title
RSA-RCT: Attune S+ TKA Versus Sigma TKA
Acronym
APKnee2-S+
Official Title
A Clinical Randomized Controlled RSA Trial Comparing the Cemented Attune (S+ Tibia Tray) Fixed Bearing Cruciate Retaining Knee System With the Cemented PFC Sigma Fixed Bearing Cruciate Retaining Knee System
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 16, 2019 (Anticipated)
Primary Completion Date
September 1, 2022 (Anticipated)
Study Completion Date
April 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Peter den Hollander
Collaborators
Leiden University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
The PFC Sigma Knee by DePuy Synthes is an excellent knee replacement with an excellent clinical track record, good survival rates (98% 10 years survival in patients aged < 55 years) and minimal early migration as measured with RSA (0.5mm MTPM at two years follow-up).
The Attune Knee by DePuy Synthes is an advancement in knee replacement options. It is designed to provide better range of motion and address the unstable feeling some patients experience during everyday activities, such as stair descent and bending. To date, more than 470,000 patients have received an Attune Knee and positive feedback was received regarding patient recovery, stability and motion.
The objective of this study is to accurately assess and compare migration, clinical and radiological outcome and patient reported outcomes of two knee prostheses: the Cemented Attune Fixed Bearing Cruciate Retaining Knee System and the Cemented PFC Sigma Fixed Bearing Cruciate Retaining Knee System, both by DePuy Synthes, Warsaw, Indiana, USA. The primary objective of this study is to compare the magnitude and pattern of migration of the prostheses (Femoral and Tibial component). The secondary objective of this study is to compare clinical and radiological outcome of the prostheses and PROMS.
This study is designed as a single-blind, randomized trial between the Attune Knee System and PFC Sigma Knee System. 32 patients with the Attune Knee System and 32 patients with PFC Sigma Knee System will be included in this study.
The study population will consist of patients with symptomatic osteoarthritis of the knee scheduled for knee replacement surgery at the Department of Orthopaedics, Haags Medisch Centrum The Hague (HMC), The Netherlands. Annually 350 TKA procedures are performed in this department, of which about 90% is Osteo Arthritis (OA) and 10% Rheumatoid Arthritis (RA) and other indications. We anticipate that inclusion can be accomplished within a 1 year period and that the total study duration is 3 years.
Main study parameters/endpoints are:
Migration, measured by means of RSA.
Patient Reported Outcome Measures by means of questionnaires.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis Arthritis, Joint Disease, Musculoskeletal Disease, Rheumatic Diseases
Keywords
Comparative Study, Knee Prosthesis, Prosthesis Design, Treatment Outcome, Follow-Up Studies
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
64 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ATTUNE
Arm Type
Experimental
Arm Description
Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
Arm Title
PFC Sigma
Arm Type
Active Comparator
Arm Description
Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Intervention Type
Device
Intervention Name(s)
ATTUNE S+ Knee Prosthesis by DePuy
Intervention Description
Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
Intervention Type
Device
Intervention Name(s)
PFC Sigma Knee Prosthesis by DePuy
Intervention Description
Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Primary Outcome Measure Information:
Title
Migration, Maximum Total Point Motion (MTPM in mm) measured by means of Radiostereometry (RSA)
Description
Compare the magnitude and pattern of migration of the prostheses (Tibial and Femoral component, smaller MTPM is better)
Migration is defined as the relative movement of the prosthesis with respect to the markers in the bone.
MTPM is defined as Maximum Total Point Motion, which means the amount of motion of the point that moves the most.
Time Frame
2 Years
Secondary Outcome Measure Information:
Title
EQ-5D with 3 levels of severity for each of the 5 dimensions (EQ-5D-3L)
Description
General Health: EuroQol 3 Dimensional (EQ-5D) Health Questionnaire measured using patient questionnaire; Index, 0 (worst possible) - 100 (best possible).
Time Frame
2 Years
Title
Knee injury and Osteoarthritis Outcome Score (KOOS-PS)
Description
Knee Function: Knee injury and Osteoarthritis Outcome Score (KOOS) measured using patient questionnaire; Index, 0 (worst possible) - 100 (best possible).
Time Frame
2 Years
Title
Visual Analogue Scale (VAS) pain
Description
Pain score after activity and during rest; Likert scale 0 (no-pain) -10 (extreme pain).
Time Frame
2 Years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is diagnosed with osteoarthritis and requires primary knee arthroplasty
All consecutive patients ("usual care") are included to prevent selection bias in the migration analysis.
Patient is capable of giving informed consent and expressing a willingness to comply with this study
Exclusion Criteria:
The patient has an a-priori risk for a posterior-stabilized total knee arthroplasty.
Insufficiency of the posterior cruciate ligament (PCL)
Status after patellectomy
In case flexion is less than 90 degrees
The patient is diagnosed with Rheumatoid Arthritis
When it is expected that the tibia cut during surgery will compromise the attachment of the PCL (because of bony defects)
The patient is unable or unwilling to sign the Informed Consent specific to this study
The patient does not understand the Dutch or English language good enough to participate
Patients indicated for revision arthroplasty instruments because of bone defects or deformity of the bone
When there are not enough markers visible in the baseline RSA photograph and it will not improve by placing the patient in another position, the patient will be excluded from the study (secondary exclusion criteria).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peter Hollander, MD
Phone
+31 88 979 8087
Email
P.den.Hollander@haaglandenmc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Bart K Kaptein, PhD
Phone
+31715264542
Email
B.L.Kaptein@lumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Hollander, MD
Organizational Affiliation
Haaglanden Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rob G Nelissen, Prof.
Organizational Affiliation
Leiden University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Haaglanden Medical Center
City
The Hague
State/Province
Zuid Holland
ZIP/Postal Code
2501CK
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter den Hollander, MD
Phone
+31 88 979 8087
Email
p.den.hollander@haaglandenmc.nl
First Name & Middle Initial & Last Name & Degree
Peter den Hollander, MD
First Name & Middle Initial & Last Name & Degree
Rob G Nelissen, Prof
First Name & Middle Initial & Last Name & Degree
Bart L Kaptein, PhD
12. IPD Sharing Statement
Learn more about this trial
RSA-RCT: Attune S+ TKA Versus Sigma TKA
We'll reach out to this number within 24 hrs